November 4, 2021 10:10 AM EDT
R&D

Chimerix un­rolls ear­ly win for glioma drug picked up ear­li­er this year in ac­qui­si­tion

Paul Schloesser

Associate Editor

Small biotech Chimerix made a big bet ear­ly this year when it bought out On­co­ceu­tics and lead drug ONC201 for gliomas. Now, that in­vest­ment is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

Reg­u­la­to­ry RNA start­up CAMP4 files for IPO as more biotechs line up list­ings

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times